HK1035493A1 - Muscarinic antagonists in the treatment of presbyopia - Google Patents

Muscarinic antagonists in the treatment of presbyopia

Info

Publication number
HK1035493A1
HK1035493A1 HK01106162A HK01106162A HK1035493A1 HK 1035493 A1 HK1035493 A1 HK 1035493A1 HK 01106162 A HK01106162 A HK 01106162A HK 01106162 A HK01106162 A HK 01106162A HK 1035493 A1 HK1035493 A1 HK 1035493A1
Authority
HK
Hong Kong
Prior art keywords
presbyopia
treatment
muscarinic antagonists
cholinergic
restore
Prior art date
Application number
HK01106162A
Other languages
English (en)
Inventor
Arlene Gwon
Mussie Elizabeth Wolde
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1035493A1 publication Critical patent/HK1035493A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK01106162A 1998-07-30 2001-08-31 Muscarinic antagonists in the treatment of presbyopia HK1035493A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/126,064 US6291466B1 (en) 1998-07-30 1998-07-30 Cholinergic agents in the treatment of presbyopia
PCT/US1999/016260 WO2000006135A2 (en) 1998-07-30 1999-07-22 Cholinergic agents in the treatment of presbyopia

Publications (1)

Publication Number Publication Date
HK1035493A1 true HK1035493A1 (en) 2001-11-30

Family

ID=22422802

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106162A HK1035493A1 (en) 1998-07-30 2001-08-31 Muscarinic antagonists in the treatment of presbyopia

Country Status (13)

Country Link
US (2) US6291466B1 (xx)
EP (1) EP1100480B1 (xx)
JP (1) JP2002521429A (xx)
KR (1) KR20010079593A (xx)
CN (1) CN1157186C (xx)
AT (1) ATE250412T1 (xx)
AU (1) AU754588B2 (xx)
BR (1) BR9912599A (xx)
CA (1) CA2339093A1 (xx)
DE (1) DE69911620T2 (xx)
ES (1) ES2207963T3 (xx)
HK (1) HK1035493A1 (xx)
WO (1) WO2000006135A2 (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367099B (es) 2006-07-11 2019-08-05 Refocus Group Inc Protesis escleral para tratar presbiopia y otros transtornos del ojo y dispositivos y metodos relacionados.
US8911496B2 (en) 2006-07-11 2014-12-16 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
PT1938839E (pt) * 2006-12-18 2009-09-30 Jorge Luis Benozzi Composições oftálmicas de estimulantes parassimpáticos e anti-inflamatórios para utilização no tratamento de presbiopia
GB0711151D0 (en) * 2007-06-11 2007-07-18 Sra Dev Ltd Switch for use with an ultrasonic surgical tool
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP2512492A1 (en) * 2009-12-14 2012-10-24 University of Massachusetts Methods of inhibiting cataracts and presbyopia
KR20140035363A (ko) * 2011-04-07 2014-03-21 수캄포 아게 안정피로 치료 방법
WO2013041967A2 (en) 2011-09-20 2013-03-28 Altavista Instituto De Investigation Medica S.A.S Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
EP2968239B1 (en) 2013-03-14 2019-04-24 The University of Massachusetts Methods of inhibiting cataracts and presbyopia
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CA2939427A1 (en) * 2014-02-11 2015-08-20 Vid D.O.O. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
AU2016280616B2 (en) 2015-06-18 2020-10-22 Lenz Therapeutics, Inc. Compositions for the improvement of distance vision and the treatment of refractive errors of the eye
EA035402B1 (ru) 2015-11-13 2020-06-08 Зе Юниверсити Оф Массачусеттс Бифункциональные молекулы, содержащие полиэтиленгликоль, для подавления катаракт и пресбиопии
CH711969A2 (it) * 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
AU2017311636B2 (en) 2016-08-19 2023-08-10 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
MX2020004666A (es) * 2017-11-17 2022-01-26 Cellix Bio Private Ltd Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
KR20230079489A (ko) * 2018-04-24 2023-06-07 알러간, 인코포레이티드 안구 증상의 치료를 위한 필로카르핀 염산염의 용도
EP3860600A4 (en) * 2018-10-06 2022-07-20 Biotheravision, Inc OPHTHALMIC PREPARATIONS OF A MUSCARINA GONIST AND METHOD OF USE
CN110496215A (zh) * 2019-08-23 2019-11-26 中国人民解放军总医院 一种治疗老视的水性滴眼液及其制备方法
MX2023002946A (es) * 2020-09-11 2023-04-11 Intratus Nevada Inc Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida.
JP7062846B1 (ja) * 2020-10-14 2022-05-06 参天製薬株式会社 安定な医薬組成物
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US20230263727A1 (en) 2022-01-14 2023-08-24 Somerset Therapeutics, Llc Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods
US11857539B2 (en) 2022-02-09 2024-01-02 Somerset Therapeutics, Llc Gel ophthalmic formulations of pilocarpine and brimonidine compounds and related methods
TW202404607A (zh) * 2022-03-30 2024-02-01 日商參天製藥股份有限公司 醫藥製劑之滅菌法與包裝體

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2638970A1 (fr) 1988-11-16 1990-05-18 Corbiere Jerome Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
EP0478694B1 (en) 1989-06-21 1997-01-15 The Trustees Of The University Of Pennsylvania use of pirenzepine, telenzepine oder O-methoxy -sila-hexocyclium in the manufacture of a medicament for the TREATMENT AND CONTROL OF OCULAR DEVELOPMENT
EP0648118A1 (en) 1992-07-02 1995-04-19 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia

Also Published As

Publication number Publication date
EP1100480B1 (en) 2003-09-24
CN1311670A (zh) 2001-09-05
US6291466B1 (en) 2001-09-18
US6410544B1 (en) 2002-06-25
AU5216099A (en) 2000-02-21
DE69911620D1 (de) 2003-10-30
JP2002521429A (ja) 2002-07-16
KR20010079593A (ko) 2001-08-22
AU754588B2 (en) 2002-11-21
ATE250412T1 (de) 2003-10-15
CN1157186C (zh) 2004-07-14
ES2207963T3 (es) 2004-06-01
WO2000006135A2 (en) 2000-02-10
BR9912599A (pt) 2001-05-02
DE69911620T2 (de) 2004-07-29
WO2000006135A3 (en) 2000-03-23
EP1100480A2 (en) 2001-05-23
CA2339093A1 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
HK1035493A1 (en) Muscarinic antagonists in the treatment of presbyopia
BR0007699A (pt) Métodos para restaurar e/ou melhorar a acomodação de pseudofaquia
NZ334063A (en) use of a combination of a histamine H1 receptor antagonist and a histamine H3 receptor antagonist to treat upper airway allergic responses
HK1040053A1 (en) Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
NO992755D0 (no) Protese for °yets senehinne for behandling av presbyopi og andre forstyrrelser i °yner
LV12603A (en) Method of treating hyperproliferative vascular disease using rapamycin eventually in combination with mycophenolic acid
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
IL141067A0 (en) Treatment of addiction and addiction-related behavior
NZ310767A (en) Use of an immunosuppressive or non-immunosuppressive pipecolic acid derivative for treating neurological disorders
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
ATE394107T1 (de) Vorbeugung und behandlung von kolonadenom oder kolonmikroadenom mit 6-fluorursodeoxycholsäure
MY106528A (en) Method of treating impotence.
HK1043723A1 (en) Improved scleral prosthesis for treatment of presbyopia and other eye disorders
KR920702622A (ko) 안구 발육의 치료 및 조절
PT1007093E (pt) Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas
ATE214278T1 (de) Verfahren und medikament zum vermindern des jet- lags
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
EP0797994A3 (en) Use of one or more 5-HT2 receptor antagonists in the manufacture of a medicament for treating the symptoms of venomous bites and stings
Cuypers et al. Therapy of cluster headache with histamine H1 and H2 receptor antagonists
EP1007050A4 (en) METHOD FOR THE TREATMENT OF DRUG ADDICTION
ATE306269T1 (de) Behandlung der exzessiven aggressivität mit olanzapine
EP0349589A4 (en) PHARMACOLOGICALLY ACTIVE CHOLINERGE PREPARATIONS AND METHOD FOR THE PRODUCTION AND THEIR USE FOR TREATING DISEASES.
EP1019066A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ESTOMAC BURNS
TR200101892T2 (tr) Hafıza bozukluklarının tedavisi veya önlenmesi için fankuinonun kullanımı.
Ellison et al. Penetration of I super (125) labelled N. nigricollis venom in relationship to effects on the corneal erosion syndrome in albino and pigmented rabbits.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20070722